RecruitingNot ApplicableNCT07090005

Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients

Comparing the Efficacy and Safety of the EndoZipTM System and Apollo Endoscopic Sleeve Gastroplasty (ESG), Followed by Behavioral Modifications, in Obese Patients Who Have Not Achieved Weight Reduction Through Non-surgical Methods.

Sponsor

Nitinotes Surgical Ltd.

Enrollment

184 participants

Start Date

Nov 14, 2025

Study Type

INTERVENTIONAL

Conditions

Obesity Overweight

Summary

evaluation of the EndoZip system procedure compared to the Apollo ESG procedure in obese patients.

Eligibility

Min Age: 21 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called EndoZip System and a medical device called OverStitch Endoscopic Suturing System (ESG) for people with obesity and overweight. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 21 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEEndoZip System

The EndoZip System is a single-use automated suturing device, designed to create multiple internal gastric segmentations in the stomach using an endoscopic approach.

DEVICEOverStitch Endoscopic Suturing System (ESG)

The OverStitch ESG is suturing device, designed to create manual suturing in the stomach using an endoscopic approach.

Locations(2)

Cedars Sinai Medical Center

Los Angeles, California, United States

Lenox Hill Hospital | Northwell Health

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07090005

Related Trials

A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body

NCT074073481 location

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

NCT072258161 location

A Study of LY3971297 in Healthy Participants

NCT061482727 locations

Evaluation of the Care Pathway Offered by the "Chronic Disease Unit" to Obese Patients

NCT065382201 location

Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

NCT0749788023 locations